[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369168-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369168-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mechanisms-of-resistance-to-ret-directed-therapies","Mechanisms of resistance to RET-directed therapies","","The association between RET and multiple endocrine neoplasia type 2 was established in 1993 and remains one of the few oncogenes with distinct phenotypes linked to the same hot-spot variants in germline or somatic DNA. Somatic RET fusions occur in multiple cancers, and highly selective RET inhibitors have improved outcomes. Primary and acquired resistance arise from on-target RET alterations or bypass via alternate pathways, evolving through stochastic subclonal events, making resistance mechanisms essential for identifying new therapeutic opportunities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mechanisms-of-resistance-to-ret-directed-therapies/369168/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mechanisms-of-resistance-to-ret-directed-therapies/369168.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is RET and why is it clinically important in cancer?","Question",{"text":63,"@type":64},"RET encodes a receptor tyrosine kinase and is linked to multiple endocrine neoplasia type 2 through specific hot-spot variants. These same RET alterations also occur somatically in several cancers, driving the development of RET-targeted therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do RET-directed therapies develop resistance?",{"text":68,"@type":64},"Resistance can be on-target, due to additional genomic alterations within RET, or bypass, where alternate oncogenic pathways replace RET signaling. The paper notes that these mechanisms are seen across multiple cancer types and can reflect evolution away from RET dependence via stochastic subclonal events.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the role of highly selective RET inhibitors, and why is more work still needed?",{"text":72,"@type":64},"Selective RET inhibitors have improved outcomes and were generally well tolerated. However, while compounds reported to address bypass oncogenes show at least short-term success, on-target RET-resistance strategies have not yet translated into routine clinical practice, making this an urgent need.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369168,1791279640,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Endocrine-Related Cancer (2025) 32 e240224  \n[https://doi.org/10.1530/ERC-24-0224](https://doi.org/10.1530/ERC-24-0224)  \nREVIEW  \nReceived 25 August 2024  \nAccepted 10 December 2024 Available online 10 December 2024  \nVersion of Record published 10 January 2025  \n\n| Mechanisms of resistance to RET-directed therapies\u003Cbr>Roderick J Clifton-Bligh􀀁\u003Cbr>Cancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, New South Wales, Australia\u003Cbr>Correspondence should be addressed to R J Clifton-Bligh: [roderick.cliftonbligh@sydney.edu.au](roderick.cliftonbligh@sydney.edu.au)\u003Cbr>This paper forms part of the themed collection RET@Thirty: Three Decades of Remarkable Progress. The guest editors for this collection were Tom Kurzawinski, Neil McDonald and Kate Newbold. |\n| --- |\n| Abstract\u003Cbr>The association between RETand multiple endocrine neoplasia type 2 was established in 1993 and remains one of the very few oncogenes for which distinct phenotypes (medullary thyroid cancer or pheochromocytoma) are associated with the same hot-spot variants occurring in either germline or somatic DNA. Somatic RET fusion events have also been described in several cancers, including papillary thyroid cancer, non-small-cell lung cancer, breast cancer, salivary gland cancer and pancreatic cancer. Highly selective RET inhibitors have improved outcomes in RET-altered cancers and have been well-tolerated. Nevertheless, primary and acquired drug resistance has been observed, arising from distinct genomic alterations either in RET (on-target resistance) or via alternate oncogenic pathways (bypass resistance) . The same mechanisms of resistance have been observed across multiple cancer types, which implies RET-altered cancers evolve away from RET addiction via stochastic subclonal events. Understanding these mechanisms is crucial for identifying therapeutic opportunities to overcome resistance. Successful treatment targeting bypass oncogenes has been reported in several instances, at least for short-term outcomes; in contrast, although several compounds have been reported to overcome on-target RET alterations, none have yet been translated into routine clinical practice and this remains an area of urgent clinical need.\u003Cbr>Keywords: RET; medullary thyroid cancer; selpercatinib; pralsetinib |\n\nIntroduction  \nAfter the cloning of rearranged during transfection (RET) proto-oncogene on chromosome 10q11.2 (Takahashi et al. 1985), its association with various human malignancies was progressively uncovered: ﬁrst, with ﬁnding somatic RET rearrangements (as fusion genes) in up to 20% papillary thyroid cancers (PTC) (Grieco et al. 1990, Viglietto et al. 1995) and then establishing RET germline mutations as the cause of multiple endocrine neoplasia type 2A (MEN2A) (Donis-Keller et al. 1993, Mulligan et al. 1993) and MEN2B (Carlson et al. 1994, Eng et al. 1994, Hofstra et al. 1994) . Since then, hot-spot mutations in RET exons 8, 10, 11 and 13–16 and rarely 1 and 5 have been  \nfound in nearly all cases of MEN2A and 2B syndromes (Gild et al. 2023) . Remarkably, the same mutations (most commonly M918T; this review will use amino acid terminology commonly used by clinicians throughout, i.e. M918T instead of p.Met918Thr) also occur somatically in around 25–50% of sporadic medullary thyroid cancers (MTC) (Romei et al. 2016) . Somatic RET rearrangements (as fusion genes with CCDC6, NCOA4, KIF5B, PRKAR1A, TRIM33 and other rarer partners) have now been found in 1–2% of non-small-cell lung cancers (NSCLC) and at lower prevalence in many other cancers including pancreatic, colon, breast and  \nPublished by Bioscientiﬁca Ltd.  \n[https://erc.bioscienti](https://erc.bioscienti)ﬁ[ca.com](ca.com)  \n© 2025 the author(s)  \nThis work is licensed under a Creative Commons Attribution 4 .0 International License.  \nR J Clifton-Bligh Endocrine-Related Cancer (2025) 32 e240224  \n[https://doi.org/10.1530/ERC-24-0224](https://doi.org/10.1530/ERC-24-0224)  \nsalivary g","cbCaioQEr6DXUsbi","https://ap.wps.com/l/cbCaioQEr6DXUsbi","pdf",1755912,12,"English","# Abstract\n# Introduction","[{\"question\":\"What is RET and why is it clinically important in cancer?\",\"answer\":\"RET encodes a receptor tyrosine kinase and is linked to multiple endocrine neoplasia type 2 through specific hot-spot variants. These same RET alterations also occur somatically in several cancers, driving the development of RET-targeted therapies.\"},{\"question\":\"How do RET-directed therapies develop resistance?\",\"answer\":\"Resistance can be on-target, due to additional genomic alterations within RET, or bypass, where alternate oncogenic pathways replace RET signaling. The paper notes that these mechanisms are seen across multiple cancer types and can reflect evolution away from RET dependence via stochastic subclonal events.\"},{\"question\":\"What is the role of highly selective RET inhibitors, and why is more work still needed?\",\"answer\":\"Selective RET inhibitors have improved outcomes and were generally well tolerated. However, while compounds reported to address bypass oncogenes show at least short-term success, on-target RET-resistance strategies have not yet translated into routine clinical practice, making this an urgent need.\"}]","Mechanisms of resistance to RET-directed therapies | PDF",1790181145,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23cd0a635df8c9c3057b0be73d84fbe5.webp",983,1269,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23902813ee67f6782ae79827a066c926.webp",982,1268,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95c886e19ac140b08cd740a12a6e1089.webp",981,1266,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd928c9c27d4881f67d2f8e553de9a4d.webp",980,1265]